



21 September 2026

Sydney, Australia

Nyrada Successfully Raises AU\$12.0 Million Via Placement

Highlights:

- Nyrada has successfully raised AU\$12.0 million of new equity capital (before costs) by way of a Placement to institutional, sophisticated, and professional investors.
- Placement follows recent commencement of Nyrada's Phase IIa to assess safety and preliminary efficacy of Xolatryp® in reducing heart tissue damage and improving heart function in patients suffering a heart attack.
- Nyrada Board will participate in the placement in the amount of AU\$5.125 million. Director participation is subject to CDI holder approval at a General Meeting estimated to be held in February 2027.
- Nyrada will also undertake a Securities Purchase Plan on substantially the same terms as the Placement targeting an additional AU\$2.0 million of new equity capital (before costs).
- Funds raised will be used to advance and accelerate Nyrada's clinical programs, execution and strategic development support, and general working capital, corporate costs, and offer costs.

Nyrada Inc. (ASX:NYR), a clinical stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today announces it has received firm commitments for a placement of approximately 19.4 million CHES Depositary Instruments (CDIs), raising AU\$12.0 million in new equity capital from new and existing professional and sophisticated investors ("Placement").

Capital Raise Terms:

The Placement issue price was AU\$0.62 per CDI, representing a 15.1% discount to the last traded price and an 11.4% discount to the 5-day volume weighted average price (VWAP) of Nyrada's CDIs. A Securities Purchase Plan (SPP) will also be undertaken on substantially the same terms (see below).

Participants in both the Placement and the SPP will each receive, for nil consideration, three (3) attaching options for every four (4) new CDIs subscribed for ("Attaching Options") and one (1) piggyback option for every Attaching Option exercised ("Piggyback Option").

The issue of Piggyback Options to SPP participants is subject to Nyrada obtaining ASIC relief from Section 716(1) of the Corporations Act 2001 (Cth). Should relief not be granted, SPP participants will instead receive one (1) attaching option for every one (1) CDI subscribed for ("Revised SPP Attaching Option") in lieu of both the Attaching Options and Piggyback Options.



The Attaching Options and Revised SPP Attaching Options will each have an exercise price of AU\$0.93 and will expire on 25 September 2028. The Piggyback Options will have an exercise price of AU\$1.40 and will expire on 26 September 2030.

The Company will seek quotation of both the Attaching Options (and if applicable Revised SPP Attaching Options) and Piggyback Options which will be subject to satisfying ASX's requirements (including but not limited to minimum holder spread requirements for quotation). Subject to holders exercising their Attaching Options, Piggyback Options will be issued on approximately 2 October 2028.

Bell Potter Securities Limited (Bell Potter) acted as sole lead manager and bookrunner to the capital raise. Based on a \$14.0 million total raise (\$12.0 million placement and \$2.0 million SPP), Bell Potter will receive 3.85 million unlisted options over CDIs ("Broker Options"). The exercise price for these Broker Options is AU\$0.93 and the exercise period will expire on 25 September 2029.

Nyrada Managing Director and CEO, James Bonnar commented: "This capital raise marks a pivotal moment for Nyrada. The strong support from both new and existing investors is a powerful validation of our science, our team, our novel drug Xolatryp®, and our potential to address serious unmet clinical needs. We are now well-positioned to complete our Phase IIa trial and fortify our business by enhancing our pipeline, develop an oral dose TRPC asset, and developing a commercial dose form of Xolatryp.

"We are extremely grateful to investors for sharing our vision, and we look forward to an important period of execution ahead."

Nyrada Chair, John Moore commented: "Thank you to all CDI holders, existing and incoming, for your support. Nyrada is at a crucial juncture and well capitalised to progress the development of Xolatryp, our first-in-class small molecule therapy."

The Nyrada Board will participate in the placement in the amount of AU\$5.125 million on the same terms as the Placement. Director participation is subject to CDI holder approval at a forthcoming General Meeting (EGM), estimated to be held in February 2027. A formal Notice of Meeting confirming the date of the EGM will be issued in due course.

Use of Placement Proceeds:

In addition to Nyrada's existing cash reserves, the Company will use the net proceeds of the Placement for the following:

- Complete its Phase IIa clinical trial of Xolatryp in cardiac ischemia reperfusion injury;
- Undertake a Phase Ib clinical trial to assess Xolatryp as a combined anti-cancer and cardioprotection oncology drug to position for a Phase IIa clinical trial;
- Undertake a prerequisite stroke preclinical model to position Xolatryp for a Phase IIa clinical trial;
- Development of commercial dose form of Xolatryp and an orally dosed TRPC channel inhibitor; and
- Corporate, working capital, and raise costs.



The Placement, Attaching Options, and Piggyback Options (and if applicable Revised SPP Attaching Options) are within the Company's available placement capacity under ASX Listing Rule 7.1 and 7.1A. The expected settlement date for the placement is 24 September 2026, with new CDIs being issued 25 September 2026.

Indicative Placement Timetable:

Event	Date
Trading Halt Lifted	Monday 21 September 2026 (before 10.00 am AEST)
Settlement Date	24 September 2026
Issue of CDIs	25 September 2026

This timetable is indicative only and Nyrada may, at its absolute discretion, vary any of the above dates, subject to the ASX Listing Rules and the Corporations Act 2001 (Cth) and other applicable laws.

Securities Purchase Plan (SPP):

The Company will also undertake a non-underwritten Securities Purchase Plan (SPP) to raise up to another AU\$2.0 million (before costs). Each eligible CDI holder will have the opportunity to participate in the SPP by applying for up to AU\$30,000 of CDIs in Nyrada without incurring brokerage or other transaction costs. CDI holder approval is not required for the issue of new CDIs, Attaching Options, or Piggyback Options under the SPP (and if required the Revised SPP Attaching Options).

CDIs issued under the SPP will be on the same terms as those issued under the Placement, including the same issue price per CDI of AU\$0.62 and ranking equally with existing Nyrada CDIs.

SPP participants will also be eligible to receive the Attaching Options and Piggyback Options. For nil consideration, SPP participants will receive three (3) Attaching Options for every four (4) new CDIs subscribed for and one (1) Piggyback Option for every Attaching Option exercised.

As outlined above, the issue of Piggyback Options to SPP participants is subject to Nyrada obtaining ASIC relief from Section 716(1) of the Corporations Act 2001 (Cth). Should relief not be granted, SPP participants will instead receive Revised SPP Attaching Options.

If ASIC Relief Granted , SPP Participants will receive	If ASIC Relief Not Granted , SPP Participants will receive
Three (3) Attaching Options for every four (4) new CDIs subscribed for and one (1) Piggyback Option for every attaching option exercised.	One (1) Revised SPP Attaching Option for every one (1) new CDI subscribed for.

- 1) Attaching Option, exercisable at AU\$0.93 and expiry on 25 September 2028
- 2) Revised SPP Attaching Option, exercisable at AU\$0.93 and expiry on 25 September 2028
- 3) Piggyback Option, exercisable at AU\$1.40 and expiry on 26 September 2030



If the SPP is oversubscribed, at the absolute discretion of the Nyrada Board, Nyrada may scale back the number of new CDIs that will be issued to individual CDI holders under the SPP. The Nyrada Board may also decide to accept applications (in whole or in part) that result in the SPP raising more or less than AU\$2.0 million in its absolute discretion, but subject always to compliance with all applicable laws, regulations, and the ASX Listing Rules.

The record date for the SPP will be Friday 18 September 2026. The SPP will open at 9.00am (Sydney time) on 12 October 2026 and is expected to close at 5.00pm (Sydney time) on 26 October 2026.

Full details of the SPP will be set out in an SPP Offer Booklet, which is expected to be released to the ASX on 9 October 2026. Once released, eligible CDI holders are encouraged to read the SPP Offer Booklet carefully and, if in doubt as to whether to accept the offer the subject of the SPP Offer Booklet, to consult a financial or other professional adviser.

Use of Securities Purchase Plan Proceeds:

In addition to Nyrada's existing cash reserves and capital raised from the Placement, the Company will use the net proceeds of the SPP for the following:

- Complete its Phase IIa clinical trial of Xolatryp in cardiac ischemia reperfusion injury;
- Undertake a Phase Ib clinical trial to assess Xolatryp as a combined anti-cancer and cardioprotection oncology drug to position for a Phase IIa clinical trial;
- Undertake a prerequisite stroke preclinical model to position Xolatryp for a Phase IIa clinical trial;
- Development of commercial dose form of Xolatryp and an orally dosed TRPC channel inhibitor; and
- Corporate, working capital, and raise costs.

Indicative Securities Purchase Plan Timetable:

Event	Date
Record Date	18 September 2026
Announcement of SPP	21 September 2026 (before 10.00am AEST)
Opening Date	9.00 am AEDT, 12 October 2026
Closing Date	5.00 pm AEDT, 26 October 2026
Final day for Nyrada to announce the results of SPP	30 October 2026
Issue of New CDIs under SPP	30 October 2026
New CDIs commence trading on ASX	2 November 2026

This timetable is indicative only and Nyrada may, at its absolute discretion, vary any of the above dates (including the Closing Date) by sending a revised timetable to the ASX. All times are Sydney time.

-ENDS-



About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca²⁺ entry related to multiple disease pathologies.

[A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed](#) and a [Phase IIa clinical trial](#) has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI).

Key Links:

Cardioprotection

- PROTECT-MI website - <https://www.protect-mi.com>
- PROTECT-MI NIH Entry - <https://bit.ly/4cB2fF9>
- Phase IIa factsheet - <https://bit.ly/4bcDIKj>
- Preclinical cardioprotection study 1a - <https://bit.ly/4sigwMZ>
- Preclinical cardioprotection study 1b - <https://bit.ly/4rmOsXn>
- Preclinical cardioprotection study 2 - <https://bit.ly/40jHpUg>

Oncology

- Preclinical cardiomyopathy study - <https://bit.ly/4yR9BgD>
- Preclinical cardiomyopathy pilot study - <https://bit.ly/4xJH3Fj>
- Preclinical anti-tumour study - <https://bit.ly/49rWOa0>

Neuroprotection

- Preclinical traumatic brain injury study - <https://bit.ly/40fhrRT>
- Preclinical stroke study - <https://bit.ly/4sygHmH>

Foundations

- Phase I results - <https://bit.ly/3Nt0GzH>
- Preclinical mitochondria stabilisation study - <https://bit.ly/4yiZUHa>
- GLP study results - <https://bit.ly/4d8VYkX>
- CSANZ Conference Poster - <https://bit.ly/4A9ROmf>



About Nyrada Inc.

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investor & Media Enquiries:

Dimitri Burshtein

T: 0491 789 391

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@atomicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.